<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603937</url>
  </required_header>
  <id_info>
    <org_study_id>KS301P105</org_study_id>
    <secondary_id>2020-001063-82</secondary_id>
    <nct_id>NCT04603937</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)</brief_title>
  <acronym>GLIMMER</acronym>
  <official_title>A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kodiak Sciences Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kodiak Sciences Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to&#xD;
      aflibercept in participants with treatment-naïve DME.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, prospective, randomized, double-masked, two-arm, multi-center&#xD;
      non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of&#xD;
      KSI-301 5 mg in participants with treatment-naïve DME.&#xD;
&#xD;
      The primary endpoint will be assessed at Year 1; additional secondary endpoints for efficacy&#xD;
      will be assessed at Years 1 and 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized 1:1 into one of two treatment arms: KSI-301 or aflibercept.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>For masking purposes, sham injections will be administered at every monthly visit if an active treatment is not administered. To preserve masking, two investigators are required for this study. The masked Investigator will be responsible for the examinations and safety assessments. The unmasked Investigator will perform the injections and post-treatment assessments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of KSI-301 to Aflibercept measured by changes in BCVA.</measure>
    <time_frame>Day 1 to Year 1</time_frame>
    <description>Demonstrate that KSI-301 5 mg is non-inferior to aflibercept 2 mg with respect to mean change in best corrected visual acuity (BCVA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of KSI-301 5 mg compared to aflibercept 2 mg measured by changes in BCVA.</measure>
    <time_frame>Day 1 to Year 2</time_frame>
    <description>Improvement in best corrected visual acuity (BCVA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of KSI-301 5 mg compared to aflibercept 2 mg measured by changes in CST.</measure>
    <time_frame>Day 1 to Year 2</time_frame>
    <description>Improvement in central subfield thickness (CST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of KSI-301 5 mg compared to aflibercept 2 mg measured by changes in DRSS.</measure>
    <time_frame>Day 1 to Year 2</time_frame>
    <description>Improvement if the diabetic retinopathy severity score (DRSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of KSI-301 5 mg compared to aflibercept 2 mg measured by number of intravitreal injections during the study.</measure>
    <time_frame>Day 1 to Year 2</time_frame>
    <description>Mean number of intravitreal injections during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of KSI-301 mg compared to aflibercept 2 mg measured by the number of ocular and systemic adverse events.</measure>
    <time_frame>Day 1 to Year 2</time_frame>
    <description>Incidence of ocular and systemic adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>KSI-301 (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept (Arm B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KSI-301</intervention_name>
    <description>Intravitreal Injection</description>
    <arm_group_label>KSI-301 (Arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Intravitreal Injection</description>
    <arm_group_label>Aflibercept (Arm B)</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.</description>
    <arm_group_label>Aflibercept (Arm B)</arm_group_label>
    <arm_group_label>KSI-301 (Arm A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent prior to participation in the study.&#xD;
&#xD;
          2. Treatment-naïve diabetic macular edema, with vision loss and center involvement (if&#xD;
             present) diagnosed within 9 months of screening.&#xD;
&#xD;
          3. BCVA ETDRS letter score between 78 and 25 (-20/25 to 20/320 Snellen equivalent),&#xD;
             inclusive, in the Study Eye.&#xD;
&#xD;
          4. CST of ≥ 320 microns on SD-OCT (Heidelberg Spectralis or equivalent on other OCT&#xD;
             instruments) as determined by the Reading Center.&#xD;
&#xD;
          5. Decrease in vision determined by the Investigator to be primarily the result of DME.&#xD;
&#xD;
          6. Type 1 or Type 2 diabetes mellitus and a HbA1c of ≤12%.&#xD;
&#xD;
          7. Other protocol-specified inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Macular edema in the Study Eye considered to be secondary to a cause other than DME.&#xD;
&#xD;
          2. Active iris or angle neovascularization or neovascular glaucoma in the Study Eye.&#xD;
&#xD;
          3. High-risk proliferative diabetic retinopathy characteristics in the Study Eye.&#xD;
&#xD;
          4. History of Pan-retinal Photocoagulation (PRP) laser in the Study Eye within 3 months&#xD;
             of screening.&#xD;
&#xD;
          5. Tractional retinal detachment in the Study Eye.&#xD;
&#xD;
          6. Active retinal disease other than the condition under investigation in the Study Eye.&#xD;
&#xD;
          7. Any history or evidence of a concurrent ocular condition present, that in the opinion&#xD;
             of the Investigator could require either medical or surgical intervention or affect&#xD;
             macular edema or alter visual acuity during the study (e.g., vitreomacular traction,&#xD;
             epiretinal membrane).&#xD;
&#xD;
          8. Active or suspected ocular or periocular infection or inflammation in either eye at&#xD;
             Day 1.&#xD;
&#xD;
          9. Any prior use of an approved or investigational treatment for DME in the Study Eye&#xD;
             (e.g., anti-VEGF, intraocular or periocular steroids, macular laser photocoagulation).&#xD;
&#xD;
         10. Women who are pregnant or lactating or intending to become pregnant during the study.&#xD;
&#xD;
         11. Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value&#xD;
             ≥100 mmHg while at rest.&#xD;
&#xD;
         12. Recent history (within the 6 months prior to screening) of myocardial infarction,&#xD;
             stroke, transient ischemic attack, acute congestive heart failure or any acute&#xD;
             coronary event.&#xD;
&#xD;
         13. History of a medical condition that, in the judgment of the Investigator, would&#xD;
             preclude scheduled study visits, completion of the study, or a safe administration of&#xD;
             investigational product.&#xD;
&#xD;
         14. Other protocol-specified exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Velazquez-Martin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kodiak Sciences Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kodiak Sciences Inc</last_name>
    <phone>1 (650) 281-0850</phone>
    <email>ksi301clinical@kodiak.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retinal Research Institute, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Arkansas Retina Associates</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eye Medical Center of Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of San Diego</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group Inc</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southwest Eye Consultants</name>
      <address>
        <city>Durango</city>
        <state>Colorado</state>
        <zip>81301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Group of New England</name>
      <address>
        <city>Waterford</city>
        <state>Connecticut</state>
        <zip>06385</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Retina Group of N England</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Eye Microsurgical Institute</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rand Eye Institute</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Ophthalmic Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Specialists of Idaho</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Talley Eye</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maine Eye Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Group of Washington</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>New England Retina Consultants</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants PC</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>78073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vitreoretinal Surgery PA</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of NV</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vitreo Retinal Consultants</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Surgeons of Central NY</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Western NY</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asheville Eye Associates</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation, Cole Eye Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants, LLC</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston-(Katy)</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Retina Associates (Round Rock)</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston - (Woodlands)</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vitreoretinal Associates of Washington</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DME</keyword>
  <keyword>Kodiak</keyword>
  <keyword>Vascular endothelial growth factor</keyword>
  <keyword>Anti-VEGF</keyword>
  <keyword>VEGF</keyword>
  <keyword>Antibody biopolymer conjugate</keyword>
  <keyword>Retinal Degeneration</keyword>
  <keyword>Retinal Diseases</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Vision Disorders</keyword>
  <keyword>Vision, low</keyword>
  <keyword>Aflibercept</keyword>
  <keyword>Eylea</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>Diabetic macular edema</keyword>
  <keyword>Macular edema</keyword>
  <keyword>KSI-301</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

